BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30946633)

  • 21. Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center.
    Bajpai J; Chandrasekharan A; Simha V; Talreja V; Karpe A; Pandey N; Singh A; Rekhi B; Vora T; Ghosh J; Banavali S; Gupta S
    J Glob Oncol; 2018 Sep; 4():1-10. PubMed ID: 30241240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
    Verma P; Jain S; Kapoor G; Tripathi R; Sharma P; Doval DC
    J Pediatr Hematol Oncol; 2021 May; 43(4):e466-e471. PubMed ID: 32925402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.
    Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K
    Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
    Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
    Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy.
    Min D; Lin F; Shen Z; Zheng S; Tan L; Yu W; Yao Y
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):71-9. PubMed ID: 22897971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presentation and Long-term Outcome of High-grade Osteosarcoma: A Single-institution Experience.
    Berlanga P; Cañete A; Díaz R; Salom M; Baixauli F; Gómez J; Llavador M; Castel V
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):e272-7. PubMed ID: 25374283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
    Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
    Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
    J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis in pediatric osteosarcoma: impact of modern therapies.
    Hendershot E; Pappo A; Malkin D; Sung L
    J Pediatr Oncol Nurs; 2006; 23(4):176-81. PubMed ID: 16766682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société Française d'Oncologie Pédiatrique.
    Philip T; Iliescu C; Demaille MC; Pacquement H; Gentet JC; Krakowski I; Soler-Michel P; Thiesse P; Chauvin F; Blay JY; Brunat-Mentigny M
    Ann Oncol; 1999 Sep; 10(9):1065-71. PubMed ID: 10572604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
    Harris MB; Gieser P; Goorin AM; Ayala A; Shochat SJ; Ferguson WS; Holbrook T; Link MP
    J Clin Oncol; 1998 Nov; 16(11):3641-8. PubMed ID: 9817286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
    Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
    Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.
    Bacci G; Mercuri M; Briccoli A; Ferrari S; Bertoni F; Donati D; Monti C; Zanoni A; Forni C; Manfrini M
    Cancer; 1997 Jan; 79(2):245-54. PubMed ID: 9010097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma.
    Testa S; Hu BD; Saadeh NL; Pribnow A; Spunt SL; Charville GW; Bui NQ; Ganjoo KN
    Curr Oncol; 2021 Dec; 28(6):5304-5317. PubMed ID: 34940082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt.
    Morsy AM; Ahmed BM; Rezk KM; Ramadan IK; Aboelgheit AM; Eltyb HA; Abd Elbadee OM; El-Naggar MS
    J Pediatr Hematol Oncol; 2020 Mar; 42(2):e66-e78. PubMed ID: 31107367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases.
    Ward WG; Mikaelian K; Dorey F; Mirra JM; Sassoon A; Holmes EC; Eilber FR; Eckardt JJ
    J Clin Oncol; 1994 Sep; 12(9):1849-58. PubMed ID: 8083708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
    Meazza C; Cefalo G; Massimino M; Daolio P; Pastorino U; Scanagatta P; Morosi C; Podda M; Ferrari A; Terenziani M; Spreafico F; Casanova M; Parafioriti A; Collini P; Gandola L; Bastoni S; Biassoni V; Schiavello E; Chiaravalli S; Puma N; Bergamaschi L; Luksch R
    Med Oncol; 2017 Nov; 34(12):191. PubMed ID: 29094224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.